Blau Farmacêutica 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Marcelo Hahn

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	83.3%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 07

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Nov 06

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Aug 29

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Feb 01

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

May 14

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Feb 24

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Oct 14

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Aug 17

CEO

Marcelo Hahn

no data

테뉴어

Mr. Marcelo Rodolfo Hahn is the Founder and serves as Controller & Chief Executive Officer at Blau Farmacêutica S/A and serves as its Deputy Chairman of the Board. Mr. Hahn served as President at Blau Farm...

리더십 팀

이름	위치	테뉴어	보상	소유권
Marcelo Hahn	Founder	no data	데이터 없음	83.3% R$ 2.2b
Douglas Rodrigues	CFO & Investor Relations Officer	2.8yrs	데이터 없음	데이터 없음
Vanderlei Schiavo	Chief Technology	less than a year	데이터 없음	데이터 없음
Roberto Altieri	Chief Legal Officer	no data	데이터 없음	데이터 없음
Ana Luzia Ivanov	Chief People	less than a year	데이터 없음	데이터 없음
Roberto Carlos de Morais	Chief M&A and Operations (USA and Europe) Officer & Director	less than a year	데이터 없음	데이터 없음
Eliza Saito	Chief Quality Officer	less than a year	데이터 없음	데이터 없음
Eliana Sueco Samano	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Amaro de Souza Junior	Chief Business Unit Officer of Onco-Hematology and Specialties	less than a year	데이터 없음	데이터 없음
Milton Rizo	Chief Industrial Operations Officer	less than a year	데이터 없음	데이터 없음
Uilberson da Silva	Chief Research	less than a year	데이터 없음	데이터 없음
Erica Maluf	Chief Regulatory Affairs Officer	less than a year	데이터 없음	데이터 없음

0.08yrs

평균 재임 기간

경험이 풍부한 관리: BLAU3 의 관리팀은 경험 (평균 재직 기간 0.1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

Blau Farmacêutica 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Insufficient new directors

Recent updates

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 27%

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Price target increased by 11% to R$14.88

Investor sentiment improves as stock rises 15%

Price target increased by 10% to R$14.00

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 15%

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: R$0.23 (vs R$0.29 in 1Q 2023)

Price target decreased by 9.1% to R$14.29

Upcoming dividend of R$0.014 per share

Full year 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 14% to R$15.71

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 14%

Blau Farmacêutica S.A. to Report Q2, 2024 Results on Aug 06, 2024

Price target decreased by 7.9% to R$19.86

Consensus revenue estimates fall by 16%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: Revenues miss analyst expectations

Consensus EPS estimates fall by 12%

Blau Farmacêutica S.A. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.4% to R$27.39

Price target decreased by 7.1% to R$29.17

Price target decreased by 7.4% to R$31.40

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

Consensus revenue estimates decrease by 12%

Consensus EPS estimates fall by 19%

First quarter 2023 earnings released: EPS: R$0.29 (vs R$0.34 in 1Q 2022)

Price target decreased by 7.7% to R$33.91

Price target decreased by 8.3% to R$34.58

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of R$0.052 per share at 3.0% yield

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued after recent price drop

Insufficient new directors

Third quarter 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued

Now 22% undervalued

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to R$37.57

Now 21% undervalued after recent price drop

First quarter 2022 earnings: Revenues in line with analyst expectations

Insufficient new directors

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Full year 2021 earnings: Revenues in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Second quarter 2021 earnings released: EPS R$0.56 (vs R$0.50 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS R$0.58 (vs R$0.21 in 1Q 2020)

CEO

테뉴어

리더십 팀

평균 재임 기간